Six months of use of immobilumab/Infinifer in cholangiocarcinoma

The situation of patients with cholangiocarcinoma six months after receiving durvalumab/Infinifer (Durvalumab) has been a hot topic that has been widely discussed in recent years. After immunotherapy is added to the treatment plan for cholangiocarcinoma, many patients are more concerned about body response, disease control, changes in quality of life during the six months of treatment, and whether a stable state can be maintained. Clinical experience from overseas shows that durvalumab is mostly used in combination with chemotherapy. Its core goal is to help maintain disease control, delay tumor progression, and bring about a more durable immune response in some patients. The actual experience of patients is often closely related to tumor type, basic physical constitution, liver function status, and whether the treatment cycle is completed on time.

Half a year generally covers multiple treatment cycles, so patients most often encounter physical reactions caused by the superposition of immunotherapy and chemotherapy. Some patients reported that symptoms were more obvious in the first two to three months during the adaptation period and gradually stabilized in the later period; some patients maintained a good quality of life within half a year and were able to continue daily activities. The characteristic of immune checkpoint inhibitors is that the reaction may be delayed, so it is necessary to pay close attention to immune-related changes in the skin, thyroid, intestines, lungs, etc. within six months. Overseas guidelines generally recommend that patients with cholangiocarcinoma regularly monitor liver function, biliary patency, and tumor imaging during treatment to facilitate timely assessment of treatment trends.

The half-year situation is also closely related to whether the patient has regular follow-up visits. After half a year of treatment, some patients' images show that the lesions are stable or slightly reduced, which is within the acceptable clinical range. Some patients may experience changes in their condition within half a year, requiring doctors to adjust the plan in a timely manner. Importantly, durvalumab emphasizes the long-term immunomodulatory effect, so the half-year results are not final. Some patients can still maintain a long stable period after half a year, which is one of the reasons why immunotherapy has attracted attention in cholangiocarcinoma.

Reference materials:https://www.imfinzi.com/